Relay Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Relay Therapeutics, Inc. (RLAY) had Debt Securities, Available-for-sale, Amortized Cost of $791.30 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $791.30M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $437.65M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $469.77M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $504.37M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $791.30M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $437.65M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $469.77M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $504.37M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $543.00M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $616.77M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $658.03M 10-K · filed 2026-02-26 |
| 2024-09-30 | $684.74M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $555.63M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $597.90M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $606.55M 10-K · filed 2025-02-26 |
| 2023-09-30 | $662.67M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $731.75M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $782.33M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $857.54M 10-K · filed 2024-02-22 |
| 2022-09-30 | $712.54M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $742.16M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $787.95M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $679.04M 10-K · filed 2023-02-23 |
| 2021-09-30 | $387.94M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $411.21M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $463.34M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $230.35M 10-K · filed 2022-02-24 |
| 2020-09-30 | $154.01M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $174.52M 10-Q · filed 2020-08-27 |
| 2019-12-31 | $313.54M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |